RxDoctor Payments Data

Hany Guirguis, MD

Internal Medicine · Cocoa, FLNPI 1164495305

Payments from drug & device makers

$812in general payments, 2019–2025

Across 35 payments — averaging $23.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$240
  • Amgen$157
  • Shockwave Medical, Inc$139
  • Abbott$112
  • AstraZeneca$52
  • Amarin Pharma, Inc.$38
  • plus $74 from 4 others

What the payments were for

  • Food & beverage$812100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$812 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$195,923
Medicare patients
333
Services billed
1,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide108$149,940
TrulicityDulaglutide83$110,218
OzempicSemaglutide89$110,157
EliquisApixaban62$46,460
JardianceEmpagliflozin47$45,420
SymbicortBudesonide/Formoterol Fumarate68$23,709
FarxigaDapagliflozin Propanediol19$22,627
Spiriva RespimatTiotropium Bromide31$18,952
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$18,174
Tresiba Flextouch U-100Insulin Degludec36$16,510
XareltoRivaroxaban12$15,062
JanuviaSitagliptin Phosphate13$12,963
Dexlansoprazole DrDexlansoprazole23$11,119
Rosuvastatin Calcium878$10,775
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$10,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$12$260,158191 claims
Novo NordiskOzempic$240$110,15789 claims
Boehringer IngelheimJardiance, Spiriva Respimat$13$64,37378 claims
AstraZenecaSymbicort, Farxiga$52$46,33687 claims
MerckJanuvia$12$12,96313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Cocoa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →